Neovasc (NVCN) PT Lowered to $2 at Leerink Partners; 'Tiara Clinical Trials Continue to Progress'
- Tech stocks push S&P 500 to record close, buoy Nasdaq
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Coinbase (COIN) direct listing IPO reference price set at $250
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil rises after robust China data but J&J vaccine pause weighs
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Leerink Partners lowered its price target on Neovasc (NASDAQ: NVCN) to $2.00 (from $5.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monster Beverage (MNST) PT Raised to $110 at Stifel
- e.l.f. Beauty (ELF) PT Raised to $32 at Jefferies as Growing Catalysts Make Consensus Look Low
- Snap-On (SNA) PT Raised to $245 at Oppenheimer
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!